Q-omics provides the consensus-scored USP42 profile across patient tissues and cancer cell-line models. USP42 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP42 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, USP42 RNA expression shows 20,727 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where USP42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP42 survival associations across molecular data types. USP42 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP42 RNA expression–survival associations across cancer types. High USP42 expression shows unfavorable associations in ACC, LGG and CESC, but favorable associations in KIRC, UCS and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP42 RNA expression.
This table summarizes USP42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for USP42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP42 shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, LIHC, BLCA and CHOL. The HNSC box plot shows higher USP42 RNA expression in tumor versus normal tissue (log2 FC = +0.887, t-test p < 0.001).
This table shows molecular features associated with USP42 in patient tissues and cancer cell lines. In patient samples, USP42 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, USP42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
